Listen Up was the internal communications element Level Brand created to help employees learn how to improve member experience.
Klick Ideas Exchange united leading CEOs and high-level executives of biotech and pharmaceutical companies, thought leaders, and other industry influencers to explore issues that are shaping the future of healthcare.
Pfizer drops plans to split into two companies; Merck's Keytruda gains competitive edge in China; Apple may be developing health software
The consultancy includes Double Helix, which was acquired by McCann in 2012.
Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
GSK names new CEO; the FDA approves first Duchenne muscular dystrophy drug; Sanofi files Lantus patent lawsuit against Merck
Retzlaff files a complaint against Turing; Pfizer to buy antibiotics from AstraZeneca; Mylan's marketing for EpiPen faces criticism
Pfizer's commercial expertise in urology and oncology could help propel Medivation's Xtandi to new heights.
Pfizer to acquire cancer drugmaker Medivation; Valeant names new CFO; Apple acquires health data startup
The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.'s vote to exit the E.U.
Only one new osteoporosis drug has been approved over the last six years.
PhRMA and BIO, which represent life sciences firms, developed principles about sharing truthful and non-misleading information with payers and providers.
Valeant reorganizes executive team; experimental asthma drug developed by Novartis shows promising results; Teva launches generic Gleevec
The event technology platform plans to integrate a conference note-taking app developed by AstraZeneca and DigitasLBi.
Merck and Allergan reportedly vying to buy Biogen; drugmakers fight California measure capping drug prices; few seniors use the web to look for health info
A story about a boss giving away a woman's bonus to a man based on his breadwinning status resonated with Hall of Femme attendees.
Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin
Gilead reportedly avoiding paying billions in taxes; Merck plans to cut R Sage's treatment for postpartum depression meets trial goal
He is replacing Martin Golden, who was appointed head of global marketing strategy.
BI axes 725 U.S. jobs; Bill Gates supports current U.S. drug pricing; drugmakers are targeting smaller hospitals
Hillary Clinton receives more donations from pharma than republicans; biotech reps have highest salaries; NICE recommends Yervoy-Opdivo combo
According to research conducted in the first quarter, the healthcare products company has a sterling image with millennials despite a series of legal judgments against the company.
Three executives shared some of the challenges women face in the workplace and how they want to shape the next generation of female leaders.
Her hire comes as the insurance giant is merging with Humana in a $37 billion deal.
Most healthcare consumers are women, which makes it easier for female healthcare marketers to connect and understand their needs.
Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database
The healthcare agency promoted three executives to SVP and said a search for a new president is underway.
As Viagra goes generic, the pharma giant launches a feel-good corporate campaign.
Two recent polls paint a complicated picture of the public's opinion of the pharma industry.
Johnson & Johnson has appointed Michael Sneed, its worldwide VP of global corporate affairs, to the additional role of chief communications officer.
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Wednesday, October 26, 2016
- If Roche's Ocrevus is approved, the already competitive MS market will gain another player
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy